You are here

  • Home
  • Archive
  • Volume 74, Issue 6
  • Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial

Citation Tools

Article menu
Clinical and epidemiological research
Extended report
Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Eriksson JK, Karlsson JA, Bratt J, et al
Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial
Annals of the Rheumatic Diseases 2015;74:1094-1101.